$TWIN

TWIN DISC INC (TWIN): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

TWIN DISC INC (TWIN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex_1001722.htm EXHIBIT 10.1 ex_1001722.htm Exhibit 10.1 TWIN DISC, INCORPORATED AMENDED AND RESTATED 2021 OMNIBUS INCENTIVE PLAN Amended and Restated Effective August 5, 2026 ARTICLE I PURPOSE AND HISTORY 1.1 Purpose . The purpose of the Twin Disc, Incorporated Amended

Original reporting
Published Aug 11, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$TWIN
Neutral
medium confidence
Mentioned
$TWIN
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TWINNeutralLow
01

Why it matters

The document sets the maximum shares available for awards and specifies restrictions on exercisability/issuance pending shareholder approval, plus consequences if approval is not obtained by the deadline.

02

Market read

This is primarily an equity-compensation plan mechanics disclosure, with potential but indirect implications for future dilution and executive/director compensation.

03

What to watch

The key trading variable is whether shareholders approve the amended plan before the first anniversary deadline, since awards could become null and void to the extent of share-limit excess.

Relevance 6/10Novelty 3/10Timing: filed Aug 11, 2026 (SEC 8-K)

Background

The 8-K references Item 5.02 and includes Exhibit 10.1 detailing an amended and restated 2021 omnibus incentive plan effective Aug 5, 2026.

Company-level read

Ticker impact

$TWINNeutralMedium confidence
Context

Twin Disc filed an 8-K with an amended and restated 2021 omnibus incentive plan, including share-count limits and shareholder-approval conditions.

Expected impact

Likely limited near-term price impact; any effect would be indirect via expectations for future equity grants and dilution optics.

Evidence & confidence

The excerpt describes plan purpose, share authorization, and rules that awards may be null and void if shareholders do not approve by a deadline. It does not include new earnings, cash flow, or deal terms.

Market effects

Minimal sector read-through; equity-plan mechanics are company-specific.

None indicated.

None indicated.

Counterpoint

Even without operating impact, equity-plan amendments can affect dilution expectations; traders may watch for subsequent grant announcements tied to the plan.

Key entities

  • Twin Disc, Incorporated

    Subject of the 8-K and the equity incentive plan amendment described in Exhibit 10.1.

Related articles

$FEAMMed

5E Advanced Materials Secures $8 Million EXIM Investment for Fort Cady Boron Project

5E Advanced Materials (NASDAQ:FEAM) said the U.S. Export-Import Bank will invest $8 million in its Fort Cady integrated boron facility. The company said the EXIM funding precedes its application for a potential $285 million project debt facility, after receiving a letter of intent. Fort Cady is fully permitted and was highlighted by the White House under a critical minerals initiative.

$MLYSMed

Mineralys Therapeutics Q2 Earnings Call Highlights

Mineralys Therapeutics (MLYS) discussed exploratory proteomic biomarker results from its Launch-HTN and Advance-HTN trials at ENDO 2026, with management saying lorundrostat was linked to reductions in heart-failure risk biomarkers. The company expects FDA discussions to intensify near the October-November PDUFA window, and outlined U.S. payer and physician outreach ahead of a December PDUFA launch. Q2 cash was $661.4M; net loss was $241.1M.

$ABCLMedAI 8/10

AbCellera launches $200-million equity offering on heels of strong menopause trial results

AbCellera Biologics (ABCL-Q) launched a US$200 million public offering of common shares and pre-funded warrants, underwritten by Jefferies, J.P. Morgan, Cantor Fitzgerald, UBS Investment Bank and BMO Capital Markets. The deal follows strong ABCL635 hot-flash trial results (92 women), with mean hot-flash reduction 83% vs 33% placebo. Shares rose 35% Monday to $9.76.

$SERVMed

SERV Stock Slips — Uber Fully Exits Stake In Delivery Robot Maker, While Adding RIVN, LCID Shares

Uber Technologies fully sold its Serve Robotics (SERV) stake during Q2 2026, after holding over 2 million shares worth $17.5 million as of March 31, according to Uber SEC filings. Uber’s latest filing shows no SERV position. Uber added Rivian (RIVN) shares worth $339.3 million and increased Lucid (LCID) holdings. SERV fell 0.4% and UBER rose 1% on Tuesday.